Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
TransThera Sciences (Nanjing), Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to a single distinct art unit, suggesting that the pending matters involve closely related biological or pharmaceutical technologies. The use of one art unit typically allows for more consistent application of legal and technical standards across the portfolio.
Prosecution is handled by 2 distinct examiners. GONZALEZ, LUISALBERTO is the busiest examiner, with 1 pending office action currently under review. With 2 distinct examiners for the pending office actions, each application is receiving an independent evaluation. This distribution means that the company must navigate the individual preferences of two different examiners even though they are within the same art unit. For a practitioner, this requires a dual-track strategy to address the specific requirements of both assigned examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| MAYHEW, BRADLEY SCOTT | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711481 | NOVEL APPLICATION OF KINASE INHIBITOR | GONZALEZ, LUISALBERTO | — | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18552878 | COMBINED USE OF MULTIKINASE INHIBITOR | MAYHEW, BRADLEY SCOTT | 1621 | §112DP | Final Rejection | 30d | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial